The collaboration underscores a broader industry shift toward hybrid research models that integrate computational biology with advanced experimental systems
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
Pharma giant targets new standards of care
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
Shift from approvals to digital intimation via NSWS portal aims to cut timelines and boost innovation in early-stage drug development
The company said it is supporting the ongoing investigation and reiterated its commitment to patient safety.
TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility
Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
Subscribe To Our Newsletter & Stay Updated
